TY - JOUR
T1 - Targeting gut dysbiosis against inflammation and impaired autophagy in Duchenne muscular dystrophy
AU - Kalkan, Hilal
AU - Pagano, Ester
AU - Paris, Debora
AU - Panza, Elisabetta
AU - Cuozzo, Mariarosaria
AU - Moriello, Claudia
AU - Piscitelli, Fabiana
AU - Abolghasemi, Armita
AU - Gazzerro, Elisabetta
AU - Silvestri, Cristoforo
AU - Capasso, Raffaele
AU - Motta, Andrea
AU - Russo, Roberto
AU - Di Marzo, Vincenzo
AU - Iannotti, Fabio Arturo
N1 - Publisher Copyright:
© 2023 The Authors. Published under the terms of the CC BY 4.0 license.
PY - 2023/3/8
Y1 - 2023/3/8
N2 - Nothing is known about the potential implication of gut microbiota in skeletal muscle disorders. Here, we provide evidence that fecal microbiota composition along with circulating levels of short-chain fatty acids (SCFAs) and related metabolites are altered in the mdx mouse model of Duchenne muscular dystrophy (DMD) compared with healthy controls. Supplementation with sodium butyrate (NaB) in mdx mice rescued muscle strength and autophagy, and prevented inflammation associated with excessive endocannabinoid signaling at CB1 receptors to the same extent as deflazacort (DFZ), the standard palliative care for DMD. In LPS-stimulated C2C12 myoblasts, NaB reduces inflammation, promotes autophagy, and prevents dysregulation of microRNAs targeting the endocannabinoid CB1 receptor gene, in a manner depending on the activation of GPR109A and PPARγ receptors. In sum, we propose a novel disease-modifying approach in DMD that may have benefits also in other muscular dystrophies.
AB - Nothing is known about the potential implication of gut microbiota in skeletal muscle disorders. Here, we provide evidence that fecal microbiota composition along with circulating levels of short-chain fatty acids (SCFAs) and related metabolites are altered in the mdx mouse model of Duchenne muscular dystrophy (DMD) compared with healthy controls. Supplementation with sodium butyrate (NaB) in mdx mice rescued muscle strength and autophagy, and prevented inflammation associated with excessive endocannabinoid signaling at CB1 receptors to the same extent as deflazacort (DFZ), the standard palliative care for DMD. In LPS-stimulated C2C12 myoblasts, NaB reduces inflammation, promotes autophagy, and prevents dysregulation of microRNAs targeting the endocannabinoid CB1 receptor gene, in a manner depending on the activation of GPR109A and PPARγ receptors. In sum, we propose a novel disease-modifying approach in DMD that may have benefits also in other muscular dystrophies.
KW - autophagy
KW - duchenne muscular dystrophy
KW - endocannabinoid system
KW - gut microbiota
KW - short-chain fatty acids
UR - https://www.scopus.com/pages/publications/85145365649
U2 - 10.15252/emmm.202216225
DO - 10.15252/emmm.202216225
M3 - Article
C2 - 36594243
AN - SCOPUS:85145365649
SN - 1757-4676
VL - 15
JO - EMBO Molecular Medicine
JF - EMBO Molecular Medicine
IS - 3
M1 - e16225
ER -